تاثير ريشه كني هليكوباكترپيلوري در بهبود علايم سوئ هاضمه غير زخمي

Evaluation of Helicobacter pylori eradication in improvement of nonulcer dyspepsia symptoms

Objective: Non-ulcer-dyspepsia (NUD) is the fullness of abdomen after meals, early satiety, bloating but nausea or burning sensation, heart burn or pyrosis without epigastric pain. The aim of the present study was to evaluate the role of Helicobacter pylori H pylori the pathogenesis of NUD and assess the effectiveness of eradication of HP in its improvement. Subjects and Methods: This clinical trial study including 90 patients of NUD and positive for HP. Upper G[ endoscopy and rapid urease test were carried out. These patients were divided into two groups, Treatment group received omeprazole 20mg BID, furazolidone IOOmg TDS, amoxicillin 1000mg BID and bismuth subcitrate [20 rng QID) for 14 days and followed by two weeks of omeprazole 20 mg BID, The eradication of HP was confirmed by upper Gl endoscopy and antral and body biopsy for pathology six weeks after the end of treatment. The controlled group was treated with omeprazole 20 mg BID for four weeks, Both groups were treated with H2 antagonist for a further one year period. The patients were followed up at three month, six and twelve months. The data were analyzed with per protocol analysis. Results: During follow up of three, six and twelve months, the incidence of improvement in symptom in control group was greater, especially during the twelve months follow up, The improvement was statistically significant. Satisfactory improvement was seen in 28 patients (70%), unsatisfactory improvement were seen in 12 patients (30%) in treatment group, in comparison with them control group in which satisfactory improvement was seen in 16 (41%) and, unsatisfactory improvement in 21 (59%) patients (P=O,OI), The rate of improvement in clinical symptom in both group had no relationship with sex, education, psychiatric medications, occupation, cigarette smoking and the number offamily members, But significant improvement in symptoms was seen in control group patients aged less than 39 years old) P